Literature DB >> 10683330

Porcine endogenous retroviruses inhibit human immune cell function: risk for xenotransplantation?

S J Tacke1, R Kurth, J Denner.   

Abstract

Transgenic pigs are currently the most favored potential source of organs for xenotransplantation. Like all mammalian species they all harbor endogenous retroviruses in their genome. These porcine endogenous retroviruses (PERVs) are produced from several primary cells and cell lines and are able to infect human cells. Here we demonstrate that different pig strains and different animals of one strain differ in their ability to produce PERVs from normal blood cells. We report that purified PERV particles show a protein pattern typical for type C retroviruses and are antigenically related to mammalian leukemia viruses. Like most retroviruses, purified PERVs and peptides derived from the highly conserved immunosuppressive domain of their transmembrane envelope protein inhibit human immune cell functions. This indicates that high titer replication of PERVs in the transplant recipient could therefore lead to an immunodeficiency disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683330     DOI: 10.1006/viro.1999.0149

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Tracking the Fate of Endogenous Retrovirus Segregation in Wild and Domestic Cats.

Authors:  Minh Ha Ngo; MaríaCruz Arnal; Ryosuke Sumi; Junna Kawasaki; Ariko Miyake; Chris K Grant; Takeshige Otoi; Daniel Fernández de Luco; Kazuo Nishigaki
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

2.  Study of full-length porcine endogenous retrovirus genomes with envelope gene polymorphism in a specific-pathogen-free Large White swine herd.

Authors:  S Bösch; C Arnauld; A Jestin
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Transspecies transmission of the endogenous koala retrovirus.

Authors:  Uwe Fiebig; Manuel Garcia Hartmann; Norbert Bannert; Reinhard Kurth; Joachim Denner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Monitoring for presence of potentially xenotic viruses in recipients of pig islet xenotransplantation.

Authors:  O Garkavenko; M C Croxson; M Irgang; A Karlas; J Denner; R B Elliott
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

Review 5.  Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.

Authors:  Joachim Denner; Ralf R Tönjes
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

6.  Xenogeneic islet transplantation of microencapsulated porcine islets for therapy of type I diabetes: long-term normoglycemia in STZ-diabetic rats without immunosuppression.

Authors:  Thomas Meyer; Burkhard Höcht; Karin Ulrichs
Journal:  Pediatr Surg Int       Date:  2008-12       Impact factor: 1.827

7.  Detection of PERV by polymerase chain reaction and its safety in bioartificial liver support system.

Authors:  Hai-Hui Wang; Ying-Jie Wang; Hong-Ling Liu; Jun Liu; Yan-Ping Huang; Hai-Tao Guo; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

8.  Mice transgenic for a human porcine endogenous retrovirus receptor are susceptible to productive viral infection.

Authors:  Y Martina; K T Marcucci; S Cherqui; A Szabo; T Drysdale; U Srinivisan; C A Wilson; C Patience; D R Salomon
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Syncytin-1 modulates placental trophoblast cell proliferation by promoting G1/S transition.

Authors:  Qiang Huang; Jinping Li; Fengchao Wang; Matthew T Oliver; Tracy Tipton; Ya Gao; Shi-Wen Jiang
Journal:  Cell Signal       Date:  2013-01-16       Impact factor: 4.315

10.  The transmembrane protein of the human endogenous retrovirus--K (HERV-K) modulates cytokine release and gene expression.

Authors:  Vladimir A Morozov; Viet Loan Dao Thi; Joachim Denner
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.